

**From:** Fauci, Anthony (NIH/NIAID) [E]  
**Sent:** Sat, 29 Feb 2020 23:34:59 +0000  
**To:** Tom Leopold  
**Subject:** RE: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Thanks for the note. We are looking into this possibility.

Anthony S. Fauci, MD  
Director  
National Institute of Allergy and Infectious Diseases  
Building 31, Room 7A-03  
31 Center Drive, MSC 2520  
National Institutes of Health  
Bethesda, MD 20892-2520  
Phone: (b) (6)  
FAX: (301) 496-4409  
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

-----Original Message-----

From: Tom Leopold (b) (6)>  
Sent: Saturday, February 29, 2020 5:01 PM  
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6)  
Subject: Angiotensin Receptor Blockers: a possible therapy for Covid-19

Much appreciation for all of your work past and present. I am a cardiologist in New Jersey and when I read that the virus attaches to the AT2 receptors in the lungs I couldn't help but think that maybe the class of ARB's that we use so frequently for HTN and heart failure management could possibly block entry of virus into cells and prevent or mitigate the severity of infection. Has this approach ever been studied and is it worth looking into? Imagine if ARBs could lessen the severity of infection how readily available and relatively inexpensive this class of medication is! Would appreciate if someone could get back to inform me whether you received this message. Thanks. Dr Thomas Leopold Email: (b) (6)

Sent from my iPhone